Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its proposed merger with Genoptix has been scuttled after it failed to secure the necessary shareholder approval.

Rosetta said that as a result, it is obligated to reimburse Genoptix $750,000 in three installments, the first of which is due March 22. It added that Genoptix has indicated that it remains interested in pursuing a business arrangement with Rosetta, although it did not provide details about any potential deal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Independent advisors to the US Food and Drug Administration are to meet this week to discuss how they will make SARS-CoV-2 vaccine recommendations, the Washington Post reports.

The New York Times reports on how the US Food and Drug Administration has attempted to gird against pressure from the White House.

Researchers have identified a gene involved in how people determine when to urinate.

In Genome Research this week: assay for profiling chromatin accessibility, analysis of genetic variants among malaria-transmitting mosquitoes, and more.

Oct
28
Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Oct
29
Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.